ReNeuron shares in healthy shape

SHARES in ReNeuron received a shot in the arm yesterday after the life sciences company posted a positive update on its stem cell clinical trial for stroke patients at Glasgow's Southern General hospital.

Aim-quoted ReNeuron said two patients had been "successfully treated" and a third had now consented to treatment. Permission for the trial to be expanded could come as early as August, it said.

Chief executive Michael Hunt added: "ReNeuron and the clinical team in Glasgow are very encouraged by the progress of the clinical trial."

Guildford-based ReNeuron has also settled a dispute with Neuralstem, which will result in a US lawsuit being dismissed. The UK firm accepted no liability but agreed to make payments to Neuralstem, which will not affect its cashflow. Shares closed up 0.05p at 5.75p, after hitting 6.99p in early trading.